Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis

被引：9
作者：
Nie, Run-Cong [1 ]
Duan, Shu-Qiang YuanJin-Ling [1 ,3 ]
Liang, Yao [1 ]
Chen, Xiao-Jiang [1 ]
Chen, Yong-Ming [1 ]
Luo, Tian-Qi [1 ]
Chen, Guo-Ming [1 ]
Wang, Yun [2 ]
Li, Yuan-Fang [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Dept Gastr Surg,Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Hematol Oncol,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou 510060, Peoples R China
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 18期
关键词：
efficacy; immunotherapy; overall survival; PD-1; PD-L1; smoking; OPEN-LABEL; CANCER-IMMUNOTHERAPY; CHOICE CHEMOTHERAPY; SOLID TUMORS; NIVOLUMAB; PEMBROLIZUMAB; DOCETAXEL; BLOCKADE; ATEZOLIZUMAB; MULTICENTER;
D O I：
10.2217/imt-2020-0007
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Aim:This study aimed to evaluate the relationship between smoking status and efficacy of PD-1/PD-L1 inhibitors compared with conventional agents.Materials & methods:We reviewed Phase II/III trials of PD-1/PD-L1 inhibitors that reported hazard ratio (HR) in current/former and never smoking patients.Results: 15 qualifying trials comprising 9073 patients were eligible in this study. Compared with conventional agents, PD-1/PD-L1 inhibitors correlated with prolonged progression-free survival (HR: 0.73; 0.58-0.92) and overall survival (HR: 0.75; 0.71-0.80) in current/former smoker patients but not in never-smoker patients (HR: 1.15 and 0.86 for progression-free survival and overall survival, respectively; both p > 0.05) irrespective of cancer type, target of experimental agents and treatment strategy.Conclusion:There exit smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy.
引用
收藏
页码：1313 / 1324
页数：12
相关论文
共 50 条
  • [31] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. Reck, Martin;Rodriguez-Abreu, Delvys;Robinson, Andrew G.;Hui, Rina;Csoszi, Tibor;Fulop, Andrea;Gottfried, Maya;Peled, Nir;Tafreshi, Ali;Cuffe, Sinead;O'Brien, Mary;Rao, Suman;Hotta, Katsuyuki;Leiby, Melanie A.;Lubiniecki, Gregory M.;Shentu, Yue;Rangwala, Reshma;Brahmer, Julie R. NEW ENGLAND JOURNAL OF MEDICINE, 2016(19)
  • [32] Cancer immunotherapy using checkpoint blockade[J]. Ribas, Antoni;Wolchok, Jedd D. SCIENCE, 2018(6382)
  • [33] Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial[J]. Ribas, Antoni;Puzanov, Igor;Dummer, Reinhard;Schadendorf, Dirk;Hamid, Omid;Robert, Caroline;Hodi, F. Stephen;Schachter, Jacob;Pavlick, Anna C.;Lewis, Karl D.;Cranmer, Lee D.;Blank, Christian U.;O'Day, Steven J.;Ascierto, Paolo A.;Salama, April K. S.;Margolin, Kim A.;Loquai, Carmen;Eigentler, Thomas K.;Gangadhar, Tara C.;Carlino, Matteo S.;Agarwala, Sanjiv S.;Moschos, Stergios J.;Sosman, Jeffrey A.;Goldinger, Simone M.;Shapira-Frommer, Ronnie;Gonzalez, Rene;Kirkwood, John M.;Wolchok, Jedd D.;Eggermont, Alexander;Li, Xiaoyun Nicole;Zhou, Wei;Zernhelt, Adriane M.;Lis, Joy;Ebbinghaus, Scot;Kang, S. Peter;Daud, Adil. LANCET ONCOLOGY, 2015(08)
  • [34] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma[J]. Rini, Brian I.;Plimack, Elizabeth R.;Stus, Viktor;Gafanov, Rustem;Hawkins, Robert;Nosov, Dmitry;Pouliot, Frederic;Alekseev, Boris;Soulieres, Denis;Melichar, Bohuslav;Vynnychenko, Ihor;Kryzhanivska, Anna;Bondarenko, Igor;Azevedo, Sergio J.;Borchiellini, Delphine;Szczylik, Cezary;Markus, Maurice;McDermott, Raymond S.;Bedke, Jens;Tartas, Sophie;Chang, Yen-Hwa;Tamada, Satoshi;Shou, Qiong;Perini, Rodolfo F.;Chen, Mei;Atkins, Michael B.;Powles, Thomas. NEW ENGLAND JOURNAL OF MEDICINE, 2019(12)
  • [35] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Rittmeyer, Achim;Barlesi, Fabrice;Waterkamp, Daniel;Park, Keunchil;Ciardiello, Fortunato;von Pawel, Joachim;Gadgeel, Shirish M.;Hida, Toyoaki;Kowalski, Dariusz M.;Dols, Manuel Cobo;Cortinovis, Diego L.;Leach, Joseph;Polikoff, Jonathan;Barrios, Carlos;Kabbinavar, Fairooz;Frontera, Osvaldo Aren;De Marinis, Filippo;Turna, Hande;Lee, Jong-Seok;Ballinger, Marcus;Kowanetz, Marcin;He, Pei;Chen, Daniel S.;Sandler, Alan;Gandara, David R. LANCET, 2017(10066)
  • [36] Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Rizvi, Naiyer A.;Hellmann, Matthew D.;Snyder, Alexandra;Kvistborg, Pia;Makarov, Vladimir;Havel, Jonathan J.;Lee, William;Yuan, Jianda;Wong, Phillip;Ho, Teresa S.;Miller, Martin L.;Rekhtman, Natasha;Moreira, Andre L.;Ibrahim, Fawzia;Bruggeman, Cameron;Gasmi, Billel;Zappasodi, Roberta;Maeda, Yuka;Sander, Chris;Garon, Edward B.;Merghoub, Taha;Wolchok, Jedd D.;Schumacher, Ton N.;Chan, Timothy A. SCIENCE, 2015(6230)
  • [37] Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine[J]. Sakuramoto, Shinichi;Sasako, Mitsuru;Yamaguchi, Toshiharu;Kinoshita, Taira;Fujii, Masashi;Nashimoto, Atsushi;Furukawa, Hiroshi;Nakajima, Toshifusa;Ohashi, Yasuo;Imamura, Hiroshi;Higashino, Masayuki;Yamamura, Yoshitaka;Kurita, Akira;Arai, Kuniyoshi. NEW ENGLAND JOURNAL OF MEDICINE, 2007(18)
  • [38] A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization[J]. Sanmamed, Miguel F.;Chen, Lieping. CELL, 2018(02)
  • [39] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J]. Schmid, P.;Adams, S.;Rugo, H. S.;Schneeweiss, A.;Barrios, C. H.;Iwata, H.;Dieras, V.;Hegg, R.;Im, S. -A.;Wright, G. Shaw;Henschel, V.;Molinero, L.;Chui, S. Y.;Funke, R.;Husain, A.;Winer, E. P.;Loi, S.;Emens, L. A. NEW ENGLAND JOURNAL OF MEDICINE, 2018(22)
  • [40] Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel[J]. Schuette, W;Nagel, S;Blankenburg, T;Lautenschlaeger, C;Hans, K;Schmidt, EW;Dittrich, I;Schweisfurth, H;von Weikersthal, LF;Raghavachar, A;Reissig, A;Serke, M. JOURNAL OF CLINICAL ONCOLOGY, 2005(33)
12345